

The Psoriasis Association would like to make the following comment in response to the Appraisal Consultation Document for Golimumab for the treatment of Psoriatic Arthritis:-

Patients are frequently expected to, and often desire to self-care. This treatment provides the patient with this option. Patients are entitled to have a choice of treatment at the right time, and the best treatment. Golimumab provides a unique dosing regimen providing patients and clinicians with a treatment option that least impacts on daily living and quality of life. Unfortunately there is not one treatment that is successful for all people with Psoriatic Arthritis; therefore patients should be able to access all suitable treatments. Etanercept was used as the comparator, however we heard from the expert witnesses, and can see from the research evidence presented that Etanercept does not work for all patients. Indeed patients have benefited by switching to another anti-TNF therapy. The Psoriasis Association therefore feels that Golimumab should be recommended for the treatment of adults with active and progressive psoriatic arthritis when the following criteria are met (as per TA199).

- The person has peripheral arthritis with three or more tender joints and three or more swollen joints, **and**
- The psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination